Oct 1 (Reuters) - Biotechnology firm Galapagos' (GLPG.AS), opens new tab board has received non-binding offers from several groups, mainly comprised of financial investors, for its cell therapy ...

Despite major advances in oncology, cancer therapy continues to face persistent challenges due to intratumoral heterogeneity, drug resistance, and the poor clinical translation of experimental ...

Over the weekend, Ives said the launch of Apple's latest flagship devices is exceeding expectations, with demand trends already outpacing last year's cycle. "Raising price target on Apple to $310 ...